
MALI Platform
AI Stock Research
Avoro Capital Advisors LLC: latest 13F holdings
For the quarter ending 30 September 2026, Avoro Capital Advisors LLC reported 30 positions worth $9.7B in total, filed with the SEC on 16 November 2026. The quarter before, it reported $11.1B.
Read the filing at SEC EDGARChecked: the cover page's entry count and total value match the holdings table.
Top 30 positions by value
| # | Issuer | Class | Value | Weight | Shares | vs quarter before |
|---|---|---|---|---|---|---|
| 1 | UNITED THERAPEUTICS CORP | COMMON | $1.5B | 15.41% | 2,755,555 | New |
| 2 | ASCENDIS PHARMA A/S | ORDINARY SHARES | $1.2B | 11.87% | 5,050,000 | Cut 1.2% |
| 3 | KRYSTAL BIOTECH INC | COMMON | $960.7M | 9.91% | 2,888,888 | New |
| 4 | ARGENX SE | SPONSORED ADR | $958.9M | 9.89% | 1,000,000 | New |
| 5 | MADRIGAL PHARMACEUTICALS INC | COMMON | $923.9M | 9.53% | 1,833,333 | New |
| 6 | KYMERA THERAPEUTICS INC | COMMON | $835.6M | 8.62% | 7,474,747 | New |
| 7 | ARROWHEAD PHARMACEUTICALS INC | COMMON | $720.0M | 7.43% | 11,000,000 | New |
| 8 | REVOLUTION MEDICINES INC | COMMON | $440.3M | 4.54% | 2,145,000 | New |
| 9 | CYTOKINETICS INC | COMMON | $323.0M | 3.33% | 4,900,000 | New |
| 10 | DEFINIUM THERAPEUTICS INC | COMMON | $268.3M | 2.77% | 7,050,000 | New |
| 11 | STRUCTURE THERAPEUTICS INC | SPONSORED ADS | $205.0M | 2.12% | 6,555,555 | Unchanged |
| 12 | XENON PHARMACEUTICALS INC | COMMON | $204.5M | 2.11% | 5,500,000 | New |
| 13 | VERA THERAPEUTICS INC | COMMON | $182.0M | 1.88% | 5,635,000 | New |
| 14 | UNIQURE NV | COMMON | $162.5M | 1.68% | 6,727,777 | New |
| 15 | CELCUITY INC | COMMON | $119.3M | 1.23% | 1,500,000 | New |
| 16 | TAYSHA GENE THERAPIES INC | COMMON | $116.3M | 1.20% | 23,888,888 | New |
| 17 | OCULAR THERAPEUTIX INC | COMMON | $95.0M | 0.98% | 12,380,300 | New |
| 18 | DAMORA THERAPEUTICS INC | COMMON | $80.5M | 0.83% | 3,783,000 | New |
| 19 | HEMAB THERAPEUTICS HLDGS INC | COMMON | $58.4M | 0.60% | 1,892,372 | New |
| 20 | VIRIDIAN THERAPEUTICS INC | COMMON | $51.5M | 0.53% | 2,500,000 | New |
| 21 | SEPTERNA INC | COMMON | $50.9M | 0.52% | 1,300,000 | New |
| 22 | ABIVAX SA | SPONSORED ADS | $48.3M | 0.50% | 488,000 | New |
| 23 | SCRIBE THERAPEUTICS INC | COMMON | $47.8M | 0.49% | 2,598,973 | New |
| 24 | FAETH THERAPEUTICS INC | COMMON | $41.9M | 0.43% | 1,410,000 | Cut 2.4% |
| 25 | GH RESEARCH PLC | ORDINARY SHARES | $41.6M | 0.43% | 1,770,000 | Cut 1.7% |
| 26 | BIOHAVEN LTD | COMMON | $36.7M | 0.38% | 2,750,000 | New |
| 27 | AVALO THERAPEUTICS INC | COMMON | $36.5M | 0.38% | 2,377,777 | New |
| 28 | BRAVEHEART BIO INC | COMMON | $25.4M | 0.26% | 1,255,000 | New |
| 29 | WHITEHAWK THERAPEUTICS INC | COMMON | $10.7M | 0.11% | 2,849,402 | New |
| 30 | LEXEO THERAPEUTICS INC | COMMON | $1.8M | 0.02% | 525,000 | New |
New this quarter
- UNITED THERAPEUTICS CORP · $1.5B
- KRYSTAL BIOTECH INC · $960.7M
- ARGENX SE · $958.9M
- MADRIGAL PHARMACEUTICALS INC · $923.9M
- KYMERA THERAPEUTICS INC · $835.6M
- ARROWHEAD PHARMACEUTICALS INC · $720.0M
- REVOLUTION MEDICINES INC · $440.3M
- CYTOKINETICS INC · $323.0M
- DEFINIUM THERAPEUTICS INC · $268.3M
- XENON PHARMACEUTICALS INC · $204.5M
Sold out
- UNITED THERAPEUTICS CORP · was $1.5B
- KRYSTAL BIOTECH INC · was $1.1B
- MADRIGAL PHARMACEUTICALS INC · was $984.4M
- ARGENX SE · was $927.8M
- ARROWHEAD PHARMACEUTICALS INC · was $925.6M
- KYMERA THERAPEUTICS INC · was $857.1M
- REVOLUTION MEDICINES INC · was $430.2M
- CYTOKINETICS INC · was $425.9M
- CELCUITY INC · was $355.7M
- XENON PHARMACEUTICALS INC · was $348.7M
Reading a 13F
A 13F lists a manager's long positions in US-listed securities at the end of a quarter, filed up to 45 days later. It leaves out short positions, cash and most non-US holdings, so it is a partial, delayed view of a portfolio. Nothing here is investment advice.
Positions are named as the manager filed them. Values are the filing's own, in US dollars; changes compare share counts with the quarter before.